Braintree Labs & Sebela v. Lupin: Colon-Prep Patent Dispute Settles After 679 Days
Braintree Laboratories and Sebela US sued Lupin Limited and its US subsidiaries in the District of New Jersey, asserting four patents covering solid oral sulfate salt formulations used to cleanse the colon prior to medical procedures. The case was administratively terminated on April 3, 2025 following a reported settlement, with the parties given 60 days to file formal dismissal papers.
A four-patent colon-prep dispute resolved quietly out of court
Braintree Laboratories, Inc. and Sebela US, Inc. filed this infringement action on May 25, 2023 in the United States District Court for the District of New Jersey against Lupin Limited, Lupin Pharmaceuticals, Inc., and Lupin, Inc. The complaint asserted four US patents — US10143656B1, US11033498B2, US11382864B2, and US11638697B2 — all directed to solid oral sulfate salt formulations designed to cleanse the colon, a product category central to bowel preparation ahead of colonoscopies and other gastrointestinal procedures.
On April 3, 2025, the court issued an administrative termination order after the parties reported a settlement had been reached. The order is explicit that it does not constitute a dismissal under the Federal Rules of Civil Procedure; instead, the parties have 60 days to file formal dismissal papers. If those papers are not filed and no request to reopen is submitted, the court will dismiss the action with prejudice and without costs by default. The precise commercial terms of any settlement remain confidential.
At 679 days, the case ran for nearly two years before resolution — a timeline consistent with Hatch-Waxman-adjacent pharmaceutical patent disputes where ANDA filing triggers are common but not always publicly stated. The involvement of Lupin’s full US corporate structure, alongside the parent entity Lupin Limited (India), suggests the defendants anticipated significant commercial exposure. What drove the parties to settle, and any licensing or market-entry terms agreed upon, are not disclosed in the public record.
Filing to Case Terminated in 679 days
679 days from filing to administrative termination — roughly 22 months in active litigation
Case administratively terminated: what the settlement order means for both parties
Administrative termination is not a dismissal — yet
The April 3, 2025 order explicitly states it ‘shall not constitute a dismissal Order under the Federal Rules of Civil Procedure.’ The parties have 60 days to file formal dismissal papers. If they fail to do so, the court will dismiss with prejudice and without costs automatically. This two-stage process protects both sides during the period when settlement documents are being executed and any licensing terms are being finalised.
Procedural — not yet a final dismissalPlaintiffs retain leverage until formal dismissal is filed
Braintree and Sebela retain four asserted patents that were never adjudicated on the merits, meaning no invalidity or non-infringement finding has entered the public record. A settlement — particularly one that may involve a license or delayed market-entry agreement — preserves the commercial value of the patent portfolio. The patents covering solid oral sulfate colon-prep formulations remain enforceable against other potential infringers.
Patents survive — no validity rulingLupin avoids a court ruling, but settlement terms are unknown
Lupin Limited and its US subsidiaries resolved the dispute without any judicial finding of infringement or invalidity. This outcome is commercially neutral on its face — Lupin may have agreed to a license, a launch date restriction, or royalty terms. The involvement of three Lupin entities (the Indian parent plus two US subsidiaries) suggests coordinated exposure across manufacturing and distribution, and any agreed terms likely bind all three entities.
No infringement finding — terms confidentialFour colon-prep patents remain untested — competitive risk persists
Because the case settled without merits adjudication, the four patents covering solid oral sulfate salt colon-prep formulations have not been declared invalid or found infringed. Any other generic manufacturer developing a competing product must treat these patents as fully enforceable. The settlement may also have established an implied royalty benchmark, which could inform future licensing negotiations or litigation strategy for others in the gastrointestinal pharmaceutical space.
Sector risk: patents fully enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Braintree Laboratories, Inc. | Company | Pharmaceutical company — co-holder of four US patents on solid oral sulfate colon-prep formulationsSearch in Eureka ↗ |
| Co-Plaintiff | Sebela US, Inc. | Company | Search in Eureka ↗ |
| Defendant | Lupin Limited | Individual | Lupin Limited and US subsidiaries — generic pharmaceutical manufacturer facing infringement claimsSearch in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Braintree Laboratories, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Braintree Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The April 3, 2025 order is carefully drafted to preserve the court’s jurisdiction during the settlement-execution window. By explicitly stating that the order is not a dismissal under the Federal Rules of Civil Procedure, the court ensures that neither party can later argue the action was prematurely terminated. The default-with-prejudice mechanism protects judicial efficiency while giving both parties time to finalise commercial terms. No substantive findings on patent validity or infringement appear in the record.
US10143656B1 and three further patents — solid oral sulfate colon-prep formulations
The four asserted patents — US10143656B1, US11033498B2, US11382864B2, and US11638697B2 — are directed to solid oral sulfate salt formulations used to cleanse the colon, typically administered before colonoscopies and other gastrointestinal diagnostic procedures. The patent family spans application dates from 2017 (US15/669749) through 2021 (US17/347469 and US17/340973), suggesting iterative claim development around a core formulation platform. The progression from US10143656B1 to US11638697B2 is consistent with a continuation strategy designed to extend patent coverage as the product evolved commercially.
Solid oral colon-prep formulations represent a commercially significant niche within the gastrointestinal pharmaceutical market, offering patient compliance advantages over liquid alternatives. A portfolio of four patents spanning the same core technology creates overlapping layers of protection that are difficult for generic competitors to design around without triggering at least one claim. For Lupin — one of the largest generic pharmaceutical manufacturers globally — the inability to launch a competing solid oral sulfate product without risking infringement across all four patents likely created substantial commercial pressure toward settlement rather than prolonged litigation.
Should you run an FTO against US10143656B1 and the Braintree colon-prep portfolio?
Any R&D team or regulatory affairs group developing a solid oral sulfate salt bowel preparation product — whether as an ANDA filer, a branded reformulation, or a novel colon-cleansing device — should treat this four-patent portfolio as an active clearance risk. None of the four patents was adjudicated for validity or infringement in this case, and all remain in force. A freedom-to-operate analysis should map claim scope across all four patents given their overlapping but potentially distinct claim sets.
PatSnap Eureka’s FTO Search Agent can rapidly identify the claim boundaries of US10143656B1, US11033498B2, US11382864B2, and US11638697B2, surface relevant prior art that may support an IPR challenge strategy, and flag continuation applications that could extend the family further. For commercial teams tracking Braintree’s and Sebela’s enforcement posture, Eureka’s litigation monitoring module tracks new filings against the same patent numbers across all US district courts.
Run a freedom-to-operate analysis on US10143656B1 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical colon-prep patent infringement cases in US District Courts
Explore comparable patent infringement actions involving gastrointestinal pharmaceutical formulations filed in the District of New Jersey and related federal courts.
What this case signals for the gastrointestinal pharmaceutical IP landscape
Four asserted colon-prep patents, a major generic defendant, and a confidential settlement — here is what IP teams should take away.
Settlement without invalidity ruling keeps all four patents fully enforceable
No court has assessed the validity or scope of US10143656B1, US11033498B2, US11382864B2, or US11638697B2. Generic manufacturers targeting the solid oral sulfate colon-prep market face the full four-patent portfolio as an active barrier to entry. Freedom-to-operate analysis remains essential before any product launch in this category.
Lupin’s full corporate chain as defendant signals multi-jurisdictional exposure risk
The plaintiffs named Lupin Limited (India), Lupin Pharmaceuticals, Inc., and Lupin, Inc. as co-defendants. This strategy — targeting the parent manufacturer and both US distribution entities — is increasingly common in pharmaceutical patent suits and signals that plaintiffs were prepared to pursue enforcement across the full commercial chain, not just at the point of sale.
Braintree v Lupin — key questions answered
Braintree Laboratories and Sebela US asserted four US patents: US10143656B1, US11033498B2, US11382864B2, and US11638697B2. All four patents cover solid oral sulfate salt formulations used to cleanse the colon before medical procedures such as colonoscopies.
The case was administratively terminated on April 3, 2025 after the parties reported a settlement. The court’s order is explicitly not a dismissal under the Federal Rules of Civil Procedure. The parties have 60 days to file formal dismissal papers; if they do not, the court will dismiss the action with prejudice and without costs by default.
Yes. Because the case settled without any merits adjudication, no court has declared the patents invalid or found them not infringed. US10143656B1, US11033498B2, US11382864B2, and US11638697B2 remain fully enforceable against other potential infringers. Generic manufacturers in the colon-prep space should conduct freedom-to-operate analysis before launching competing products.
The plaintiffs named Lupin Limited (the Indian parent), Lupin Pharmaceuticals, Inc., and Lupin, Inc. as co-defendants — a strategy consistent with pharmaceutical patent enforcement practice where plaintiffs target the full commercial chain including the manufacturer, US distributor, and any intermediate entity. This approach maximises enforcement leverage and ensures any injunctive or monetary relief would bind all relevant corporate entities.
The 60-day period gives the parties time to finalise and execute settlement documents before filing formal dismissal papers with the court. If the parties fail to file dismissal papers or request to reopen the case within that window, the court will automatically dismiss the action with prejudice and without costs — a default mechanism that incentivises timely completion of settlement formalities without requiring further court involvement.
PatSnap Eureka searches patents and litigation data to answer instantly.